Montana High Tech Business Alliance’s Post

🔉 Promising news in cell therapy! 🤝 PhenomeX, born from Berkeley Lights' acquisition of IsoPlexis, is now set to join forces with Bruker. 🔬With over 400 instruments, PhenomeX specializes in single-cell research, unlocking insights in functional cell biology. 👉 Their advanced platforms will integrate with Bruker's solutions, propelling spatial biology initiatives. 📈 It's a strategic move that promises significant strides in antibody therapeutics and cell therapy. 👀 The $57.8 million all-stock deal is on track to close by year-end, and there are great things to come - this is one to keep an eye on. Read more from the link below Metric Search #celltherapy #cellandgenetherapy #genetherapy #biotechnology #therapeutics #antibodytherapeutics #antibody https://lnkd.in/etuSRZhM

Bone growth is regulated by a complex network of biological signaling pathways. To develop medicines for skeletal dysplasias and growth-related conditions, our research over the past two decades has been driven by a fundamental understanding of which pathway to target by leveraging one of the body’s own natural processes – and we’ve validated our approach through extensive preclinical and clinical studies. Learn more about our scientific approach: https://bit.ly/4cvb5lf

Targeting Mitochondria 2023 will be dedicated to Professor Vladimir Skulachev: A Tribute to his Vision, Discoveries, and Legacy! A ceremony will be held to honor Prof. Vladimir Skulachev's scientific achievements. Vladimir Gogvadze (Karolinska Institutet) will talk about Prof. Skulachev's strategic impact on #mitochondrialmedicine Maxim Skulachev (CSO at Mitotech S.A.) will share their recent findings from preclinical studies they completed using the latter formulations, Mitotech team successfully harnessed both the antioxidant and mild uncoupling properties of SkQ1 molecule. #WorldMitochondriaSociety #TargetingMitochondria2023 #mitochondria #clinicaltrials #mitochondrialdiseases 

At CHI's Discovery on Target Conference yesterday, Dr Zhen Wang, Principal Scientist at Depixus, presented a poster entitled ‘Single molecule real-time analysis of dynamic nucleic acid interactions’ yesterday, which attracted some excellent engagement from participants! Despite the enormous technological advances made in genomics over recent years, the latest tools still fall short in their ability to fully capture the dynamic molecular interactions within cells that are essential for understanding the underlying biology of health and disease. Based on established force spectroscopy technology, MAGNA™ is a novel platform for analyzing the complex interactions between different biomolecules, with potential application across a broad range of areas within life science research. We have already generated rich data sets revealing how nucleic acids, DNA- & RNA binding proteins, antibodies, and small-molecule compounds bind to their targets. As an example of this, we demonstrate how MAGNA™ can be used to explore the binding events between nucleic acids (in this case RNA), and ligands such as proteins and small molecule compounds, to inform the development of RNA- targeted therapeutics. @Cambridge HealthTech Institute #DrugDiscovery #RNAtherapeuitcs #Biotherapeutics #BostonDOT23 #RNA #SmallMolecules #DrugTargets #Biotech #Spectroscopy

🎉We are delighted to expand our long-standing collaboration with Fluxion Biosciences! For more than twelve years, we have been successfully offering Fluxion's innovative Bioflux systems in Germany, Austria and France. This partnership enables us to provide groundbreaking solutions for emulating in vivo conditions by introducing physiological shear flow into your research and drug discovery experiments. 🌍In addition to our current territories, we will now offer the BioFlux product range in Switzerland, the BeNeLux countries, Denmark, Sweden, Norway and Finland. This is an important step for us, enabling us to support researchers and scientists in these regions too. 🔬Hundreds of laboratories around the world rely on Fluxion Biosciences' solutions to explore novel biology, accelerate new drug development and establish therapies based on patient-specific biomarkers. The BioFlux series is renowned for the functional analysis of cellular interactions under shear flow conditions. 🤝We would like to thank our partner Fluxion Biosciences for their conficence in us and look forward to further exciting collaborations. Please do not hesitate to contact us if you have any questions or require advice. Learn more about the Fluxion BioFlux Live Cell Imaging Systems: https://t1p.de/2kt76 #research #ionchannels #liquidbiopsy #cellularanalysis #science #discovery #microfluidics #drugresearch #drugdiscovery #publications #research #biofilm #science #discovery #oralbiofilms #microbiology #quorumsensing

In Europe, the past six months have witnessed notable advancements and increased investments in European #spatial technologies... This has been driven by key commercial activities Bio-Techne acquiring small Swiss spatial bio firm Lunaphore in order to offer spatial services to their clients, OMAPiX announcing strategic partnerships with Vizgen, Resolve Biosciences, and Ultivue to offer end-to-end, large-scale, spatial profiling capabilities to customers. Furthermore, 2023 saw several European pharmaceutical companies including AstraZeneca implement the technology, seeing promising results. This has created a surge of interest in spatial biology in Europe, which will be at its peak in 2024. However, despite this optimism and investment, #spatialbiology has faced some challenges in establishing itself in #Europe, primarily due to #regulatory obstacles and ongoing #legaldisputes. Ongoing lawsuits between spatial technology vendors concerning single-cell spatial transcript profiling technologies, have led to considerable confusion and uncertainty within the field. As a result, the legal issues are influencing technology selection among pharmaceutical companies. Despite the current confusion and legal concerns, opportunities within the spatial technology space are emerging. Numerous companies continuing to explore this promising field. Furthermore, given the current climate of excitement and hesitancy among pharmaceutical companies, alongside intense competition for their attention... it is essential for the field to unite and address the challenges mentioned, while also... establishing gold standard methodologies, identifying the best technologies, and optimizing tissue selection. Learn why leading Biopharma and leading solutions providers are coming together this May: https://ter.li/3f53eo 

🔥 A new cutting-edge assay offered by Concept Life Sciences 🔥 Akoya Biosciences, Inc. Phenocode Signature Panels are designed to enable spatial characterisation of the tumour microenvironment 🔬. These 5-plex immunofluoresence panels ( DAPI) can be used to help answer fundamental questions in immuno-oncology research ▶️ Is the tumour "hot" or "cold"? ▶️ Where are the immune cells? ▶️ Are the tumour cells proliferating or lymphocytes activated? ▶️ What are the polarisation states of the TAMs? ▶️ Are the immunosuppressive cells contributing to immunotherapy resistance? You can also tailor the panel by adding an additional 6th marker. I have been really impressed with these assays. The quality of the images generated using the barcode-based technology is outstanding - a image analysts dream. The optimisation times are also greatly reduced. #phencode #immunooncology #tme #histology #multiplex #microscopy #spatial

From complex co-culture and organoids to microfluidics devices and microtissues, advanced in vitro platforms have the potential to revolutionize drug discovery. The MPS (Microphysiological Systems) World Summit 2023 kicked off in Berlin, bringing together over 1300 scientists and professionals from all over the world to discuss these tiny, but powerful, drug screening models. Axol CEO, Liam Taylor, and Product Manager, Jan Turner, attended to fly the flag for human iPSCs and how we're developing consistent, human-relevant cells at scale to fuel these advanced platforms. In this short article, we outline their 5 key highlights and takeaways from the Summit: https://hubs.la/Q021DlXP0 Want to discuss how we can supply your MPS/microfluidics devices with consistent, high-quality iPSCs? Get in contact here: https://hubs.la/Q021DlQj0 #iPSCs #organoids #microfluidics #OrganOnAChip #DrugDiscovery